“Psychiatric medications have a role in care, but we will no longer treat them as the default. We will treat them as one option, used when appropriate with full transparency and with a clear path off when they are no longer effective,” Kennedy said at the summit.
Experts say that while discussions about mental health treatments are not unwelcome, this new messaging from Kennedy and the HHS risks obscuring the benefit of antidepressants. It also raises larger concerns that most people who struggle with depression or other disorders will not actually receive the assistance that they need.
A survey published this year found that more than 16 percent of Americans reported antidepressant use—although there are significant disparities along racial lines, with Black, Hispanic, and Asian adults far less likely to use the medications than non-Hispanic white Americans. Some research has also shown that Black and Hispanic Americans are less likely to receive treatment for depression overall than their white counterparts, and have longer delays between depressive episodes and antidepressant treatment. Despite depression being the leading cause of disability worldwide according to the World Health Organization, only around 40 percent of adolescents and adults with depression in the United States received counseling or therapy between 2021 and 2023.
When Rappaport began practicing as a psychiatrist, modern antidepressants did not yet exist; the medications for treating mental disorders at the time were, according to his recollection, more difficult to use and had greater side effects. By comparison, SSRIs and SNRIs have been a “godsend,” Rappaport continued, because of their safety and ease of use. This does not mean that everyone who uses antidepressants needs to be on them for an extended period of time, he continued, but for those with severe depression, it can offer life-saving stability. Fifty percent of people who have a single episode of depression will not see a recurrence. However, for those who do see a second episode, they are 70 percent more likely to see a third, and 90 percent more likely to see another afterwards.
Physicians will emphasize the importance of addressing the needs of patients on a case-by-case basis. Psychiatry professionals from the American Society of Clinical Psychopharmacology issued guidelines for deprescribing this year suggesting that physicians should periodically review their patients’ treatments to “assure that prescribed medications remain relevant, benefits outweigh risks, and patients assume an active collaborative role in shared decision-making.”
“[Patients] may have absolutely no discontinuation symptoms when it’s tapered slowly. A few people—and we’re not sure what percentage, but it’s a small number—find it difficult to get off these medications. They have to have a prolonged taper,” said Dr. J. John Mann, the co-director of the Columbia University Center for Prevention and Treatment of Depression. “There’s no evidence, that I’m aware of, of long-term adverse effects.”
But Moutier worries that the administration’s discouragement of prescribing antidepressants could lead to people not receiving the care that they need, in part because they may be unwilling to consider medication as an option. She compared the current skepticism around antidepressants to the early 2000s, when the Food and Drug Administration issued a series of advisories warning that these medications could increase suicidal ideation among children and adolescents, and then required a “black box” warning on the labels of all antidepressants.
Antidepressant use among young adults increased in the wake of the coronavirus pandemic; around 4.5 percent of adolescents and young adults have received prescriptions for antidepressants.
Given the stigma surrounding mental disorders, depression can be considered less severe than other health issues, contributing to gaps in treatment. Mann compared the prescription of antidepressants to GLP-1 medications, which can be used for diabetes and weight loss. But he noted that when a patient who is taking GLP-1 stops using the drug, the individual can regain much of the weight that they lost. So the person may remain on the medication for an extended period of time to prevent those adverse effects. But HHS isn’t encouraging the deprescription of GLP-1 drugs, despite the adverse effects of stopping these medications.
Still, Rapaport said that he hoped raising conversations about treatment would help destigmatize mental disorders, and encourage collaboration between patients and their physicians for individualized care.
“Being able to have a conversation with the patient and really looking together about whether or not there’s an opportunity or need to simplify medication regimens, or whether there’s an opportunity to discontinue certain medicines together in a thoughtful way, is really an important discussion to have,” he said.
Hence then, the article about rfk jr s war on antidepressants could have dire consequences was published today ( ) and is available on The New Republic ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( RFK Jr.’s War on Antidepressants Could Have Dire Consequences )
Also on site :